Protara Therapeutics Inc (TARA)

08:20 AM

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times

08:20 AM

08:07 AM

Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire

08:07 AM

08:00 AM

Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan

08:00 AM

Apr 22, 2025

Examining TARA’s book value per share for the latest quarter - uspostnews.com

Apr 22, 2025

Apr 19, 2025

Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World

Apr 19, 2025

Apr 19, 2025

Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World

Apr 19, 2025

Apr 16, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nic - GuruFocus

Apr 16, 2025

Apr 16, 2025

Scotiabank Initiates Coverage of Protara Therapeutics (TARA) with Sector Outperform Recommendation - Nasdaq

Apr 16, 2025

Apr 16, 2025

Scotiabank Initiates Protara Therapeutics at Sector Outperform With $12 Price Target - marketscreener.com

Apr 16, 2025

Apr 16, 2025

Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News - GuruFocus

Apr 16, 2025

Apr 15, 2025

Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Protara Therapeutics Names Leonardo Viana Nicacio CMO - MarketScreener

Apr 15, 2025

Apr 15, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer - The Manila Times

Apr 15, 2025

Apr 15, 2025

Strategic Leadership Boost: Protara Gains 20-Year Oncology Expert as CMO Ahead of Key Trial Data - Stock Titan

Apr 15, 2025

Apr 14, 2025

Could Protara's ADVANCED-2 Trial Data Trigger A Stock Rally? - RTTNews

Apr 14, 2025

Apr 11, 2025

Protara Therapeutics to Present Interim Analysis from the Phase - GuruFocus

Apr 11, 2025

Apr 11, 2025

Commonwealth Equity Services LLC Has $195,000 Stock Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World

Apr 11, 2025

Apr 10, 2025

Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada

Apr 10, 2025

Apr 10, 2025

Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade - MSN

Apr 10, 2025

Apr 10, 2025

Protara to present bladder cancer trial data at AUA meeting - Investing.com Australia

Apr 10, 2025

Apr 10, 2025

Protara Therapeutics to Present Interim Analysis from the - GlobeNewswire

Apr 10, 2025

Apr 10, 2025

Critical Phase 2 Data Coming: TARA-002 Shows Promise in Treating Resistant Bladder Cancer - Stock Titan

Apr 10, 2025

Apr 02, 2025

Cantor Fitzgerald Initiates Coverage of Protara Therapeutics (TARA) with Overweight Recommendation - MSN

Apr 02, 2025

Mar 29, 2025

Protara Therapeutics officer sells shares worth $96,144 By Investing.com - Investing.com Australia

Mar 29, 2025

Mar 28, 2025

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results (TARA) - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

Protara Therapeutics officer sells shares worth $96,144 - Investing.com India

Mar 28, 2025

Mar 24, 2025

Cantor Fitzgerald Brokers Lower Earnings Estimates for TARA - Defense World

Mar 24, 2025

Mar 20, 2025

Cantor Fitzgerald Predicts TARA FY2025 Earnings - Defense World

Mar 20, 2025

Mar 20, 2025

Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World

Mar 20, 2025

Mar 19, 2025

Protara reveals choline deficiency in parenteral support patients By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

Protara reveals choline deficiency in parenteral support patients - Investing.com

Mar 19, 2025

Mar 19, 2025

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - GlobeNewswire

Mar 19, 2025

Mar 17, 2025

Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Cantor Fitzgerald - Defense World

Mar 17, 2025

Mar 15, 2025

Cantor Fitzgerald sets Overweight rating on Protara stock - Investing.com India

Mar 15, 2025

Mar 14, 2025

Cantor Fitzgerald Initiates Coverage on Protara Therapeutics With Overweight Rating -March 14, 2025 at 07:33 am EDT - Marketscreener.com

Mar 14, 2025

Mar 14, 2025

Analysts Set Expectations for TARA Q1 Earnings - Defense World

Mar 14, 2025

Mar 12, 2025

Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World

Mar 12, 2025

Mar 11, 2025

LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq

Mar 11, 2025

Mar 10, 2025

HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World

Mar 10, 2025

Mar 09, 2025

What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World

Mar 09, 2025

Mar 09, 2025

Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 09, 2025

Mar 06, 2025

Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks

Mar 06, 2025

Mar 06, 2025

H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK

Mar 06, 2025

Mar 06, 2025

Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Mar 06, 2025

Mar 06, 2025

Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News

Mar 06, 2025

Mar 05, 2025

Protara Therapeutics Reports Progress and Financial Results - TipRanks

Mar 05, 2025